Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.

The 2025 Clinical Trial Supply West Coast conference will gather experts to discuss US trial operations in a shifting tariff landscape.

SynOx Therapeutics has completed subject enrolment in its multi-centre Phase III TANGENT trial of emactuzumab for TGCT.

Urogen's Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.

A rise in gonorrhea infections had been predicted, but if the vaccine reaches vulnerable populations, these are now expected to decline.

HMNC said a genetic subgroup of MDD patients benefited more from BH-200 in the Phase II trial, prompting Phase III plans.

The US FDA has approved Anbogen Therapeutics’ IND application for the oral HDAC1/2/3 inhibitor ABT-301 in preparation for a Phase I/II trial.

Patients who were dosed with Praxis' vormatrigine over eight weeks experienced a 56.3% median reduction in seizure frequency.

Atavistik Bio has dosed the first subject in its Phase I clinical trial of ATV-1601, designed to treat adults with solid tumours.